Zurück zu den Rankings

Align Technology, Inc. (ALGN)

Überbewertet
HealthcareMedical Instruments & SuppliesUnited States

Fundamental

77

Kurs

$145.06

Marktkapitalisierung

$10.35B

Teil 1 · Was das Unternehmen wert ist

Übersicht

Align Technology makes Invisalign, a series of clear, custom-molded plastic trays that gradually straighten teeth as an alternative to metal braces, sold to orthodontists and general dentists who fit and monitor patients through the treatment. It also sells iTero intraoral scanners, which capture a 3D digital model of a patient's mouth used both to plan Invisalign treatment and, more broadly, for other dental and orthodontic work, plus the CAD/CAM software that runs the whole design and manufacturing process.

Wie das Geld verdient wird

Align earns Clear Aligner revenue per treatment case: a doctor orders a set of custom aligners, Align manufactures and ships them, and revenue is recognized as trays are delivered over the course of treatment. Systems and Services revenue comes from selling or leasing iTero scanners plus recurring CAD/CAM software and service fees. Because key aligner patents began expiring in 2017, pricing power now rests more on brand recognition, the doctor-training network and scanner ecosystem than on legal exclusivity.

Umsatz nach Segment

Clear Aligner80.43%

Custom clear aligner trays for straightening teeth, sold per treatment case to orthodontists and general dentists worldwide.

Systems and Services19.57%

iTero intraoral scanners plus the CAD/CAM software and services used to plan and manufacture both Invisalign and other dental work.

Wettbewerbsvorteil

Marke · Schmal

Invisalign is the name patients ask for by default, built over two decades of marketing and a large trained network of certified doctors. But the aligner patents that once blocked competitors began expiring in 2017, and cheaper rivals plus direct-to-consumer and in-office 3D-printed alternatives have since chipped away at both volume growth and pricing.

Was die Nachfrage antreibt

Mäßig zyklisch

Straightening teeth is largely elective and often paid out of pocket or through limited dental insurance, so case volumes soften when consumers pull back discretionary spending. Growth also depends on expanding into new international markets and younger teen patients, both of which move independently of any single economic cycle but are still sensitive to household budgets.

Wichtigste Risiken

  • Patent expiry and low-cost competition — Key clear-aligner patents have expired in the US and abroad, letting lower-priced rivals and direct-to-consumer aligner services compete for the same patients and pressure the prices Align can charge.
  • Discretionary consumer spending — Orthodontic treatment is often optional and expensive, so case starts slow when consumers are cautious about spending, even if their teeth alignment need has not changed.
  • International and China exposure — A meaningful part of growth depends on international markets, including China, where local competitors, economic slowdown or regulatory change can reduce case volume independent of trends in the US.
  • Intellectual property litigation — Align is involved in ongoing patent and other IP disputes with competitors and doctors; adverse rulings could restrict product features or require payments that reduce profitability.

Kundenkonzentration

Align sells to hundreds of thousands of orthodontic and dental practices worldwide rather than a few large accounts, so no single customer represents a material share of revenue.

Die Argumente dafür

Buyers argue that Invisalign's brand recognition and trained doctor network still give it the largest share of a clear aligner market that keeps growing as more patients choose aligners over metal braces, with international expansion offering years of additional case growth.

Die Argumente dagegen

Sellers fear that patent expiry has permanently opened the door to cheaper competitors, that elective treatment spending is exposed to consumer caution, and that growth increasingly depends on international markets where Align's brand advantage is weaker.

Written by the editors, published on 18. August 2026

Direct competitors

Who this company fights with for the same customers

Compare

Generated on 23. August 2026 with claude-opus-5 — shared with all users

P/E: 40.5Score: 59Market cap: $3.87B

Its Ormco unit sells the Spark clear aligner system to the same orthodontists Invisalign is sold to, competing case by case on aligner material, software and treatment planning.

P/E: —Score: 55Market cap: $1.90B

Sells SureSmile clear aligners and Primescan intraoral scanners to the same dental practices, overlapping with both of Align's businesses at once.

P/E: 10.8Score: 67Market cap: $15.24B

Its Dental Solutions arm sells Clarity aligners, brackets and bonding systems to orthodontists, competing for the same orthodontic case volume.

Straumann Holding AGSTMN

Its ClearCorrect aligner brand competes for the same orthodontic and general-dentist customers worldwide, pushed through Straumann's large European implant and digital-dentistry sales network.

Angelalign Technology Inc. (时代天使)6699

The largest clear aligner maker in China and now expanding into Europe, Latin America and Asia, taking aligner cases directly from Invisalign in the markets Align counts on for growth.

3Shape A/SNot tracked

Its TRIOS intraoral scanners are the main alternative to Align's iTero scanners in dental practices, competing for the chairside digital-scanning workflow.

Bilanz & Liquidität

Umsatz

$4.14B

Letzte 12 Monate (bis 30.6.2026)

Nettogewinn

$414M

Letzte 12 Monate (bis 30.6.2026)

Freier Cashflow

$491M

Gesamtes Eigenkapital

$4.05B

Gesamtverbindlichkeiten

$2.18B

Current Ratio

1.40

Zinsdeckungsgrad

-

Schulden/EBITDA

0.15

Gewinn je Aktie

Umsatz & Nettogewinn

Freier Cashflow

Ertragsaufschlüsselung

Historische Aufstellung

Margen im Zeitverlauf

Verschuldung im Zeitverlauf

Wie schwer die Schulden wiegen

Wachstumsraster

Wachstum — Umsatz

Innerer-Wert-Schätzung

Allgemeiner FallÜberbewertet

Innerer Wert

$118.35

Aktueller Kurs

$145.06

Sicherheitsmarge

-22.6%

Innerer-Wert-Spanne

$76.93 - $159.77

Streubreite zwischen den verwendeten Bewertungsmethoden, kein statistisch kalibriertes Konfidenzintervall.

Bewertungsmethoden

Kursziel der Analysten:$208.60
Diskontierter Cashflow (DCF):$94.10
Gewinnmultiplikator (P/E):$72.43
Graham-Wachstumsformel:$43.08
Ertragskraftwert (EPV):$43.10
Gerechtfertigtes P/B:$37.33
Dividendendiskontierung (Gordon):Nicht genügend Daten zur Berechnung
P/FFO, Funds from Operations:$145.90
Gewinn im Zyklusmittel:$206.75
Umsatzmultiplikator:$228.04
Analystenkonsens:Kaufen (16B / 8H / 1S)
Letzte Gewinnüberraschung:-0.87%

Bewertungskennzahlen

P/E-Verhältnis

25.32

ROE

10.1%

P/B-Verhältnis

2.44

P/FCF

16.30

Bruttomarge

68.0%

ROIC

9.6%

Rentabilitäts-Radar

Wertschöpfung (Wettbewerbsvorteil)

ROIC

9.6%

WACC

13.9%

ROIC − WACC

-4.3 pp

Der ROIC liegt unter den Kapitalkosten: Das Unternehmen vernichtet für jeden investierten Dollar Wert.

Fundamentalanalyse-Kriterien

Bestanden (21)

  • EPS shows upward trend
  • EPS CAGR 9.65%
  • ROIC 9.6%
  • Gross Margin 68.0%
  • P/FCF 16.30
  • P/B Ratio 2.44
  • Debt/Equity ratio
  • Operating Margin 13.2%
  • Positive Free Cash Flow
  • CapEx intensity
  • Current Ratio
  • Debt/EBITDA
  • Return on Tangible Assets
  • Low reliance on intangibles
  • ROE 10.1%
  • Revenue Growth 5Y 10.3%
  • Analyst Consensus 64% Buy
  • Earnings Surprise avg 6.3%
  • Earnings Quality (OCF/NI) 1.83
  • Share Dilution -3.1%
  • Piotroski F-Score 7/9

Nicht bestanden (4)

  • Price CAGR 4.42%
  • Price below Graham Number
  • DCF valuation (Overvalued)
  • Net Margin Trend 10.0% vs 11.0%

Nicht verfügbar (3)

  • Dividend Payout NaN%
  • Interest Coverage
  • PEG Ratio (need PE > 0 and growth > 0)

Piotroski F-Score

7/9

Starke finanzielle Gesundheit

score
criteria

Gewinnqualität

1.83

Hohe Qualität: Gewinne durch Cashflow gedeckt

Aktienverwässerung

-3.1%

Aktienrückkäufe. Aktionärsfreundlich

Institutionelle Beteiligungen

Unternehmensführung

Führungsteam

NamePositionAlter
Mr. Joseph M. HoganPresident, CEO & Director68
Mr. John F. MoriciCFO & Executive VP of Global Finance58
Mr. Zelko RelicExecutive VP & CTO60
Ms. Shirley StacyVice President of Corporate Communications & Investor Relations-
Richardson Jaime HolteExecutive Vice President of Global Human Resources-
Ms. Sreelakshmi KolliExecutive VP and Chief Product & Digital Officer50
Mr. Srini KazaExecutive Vice President of Research & Development-
Dr. Mitra DerakhshanExecutive VP, Chief Clinical Officer, Global Treatment Planning & Clinical Services-
Mr. David CarrExecutive VP and MD of EMEA-
Mr. Frank QuinnExecutive VP & MD of Americas Region-

Prüfungsrisiko

1

Vorstandsrisiko

4

Vergütungsrisiko

9

Aktionärsrechterisiko

7

Teil 2 · Der Preis und der Einstiegszeitpunkt

Dieser Teil sagt nicht, ob das Unternehmen etwas taugt: Er hilft bei der Wahl des Kaufzeitpunkts, nachdem die Fundamentaldaten überzeugt haben. Enthalten: technische Analyse, Potenzial, historische Drawdowns, Gamma-Exposure.

Dokumente

  • Jahresbericht (10-K)

    Ein jährlicher Überblick über das Geschäft, die Finanzergebnisse und die Risiken des Unternehmens.

    Eingereicht am 2026-02-27

    Dokument ansehen
  • Quartalsbericht (10-Q)

    Ein Update zur finanziellen Entwicklung der letzten drei Monate.

    Eingereicht am 2026-08-05

    Dokument ansehen
  • Ad-hoc-Meldung (8-K)

    Eine Mitteilung über ein wichtiges Ereignis, etwa einen Führungswechsel oder eine bedeutende Ankündigung.

    Eingereicht am 2026-08-31

    Dokument ansehen

via SEC EDGAR

Ertragshistorie

via SEC EDGAR

Latest News

Recent headlines for ALGN, sourced from Markets Gazette.

  • 4/7/2026POSITIVE
    Alignment Stock Surges After 2.48% Medicare Rate Hike

    Alignment Healthcare Inc. experienced a significant surge in its stock price following the Centers for Medicare & Medicaid Services (CMS) announcement of a 2.48% rate increase for 2027 Medicare Advantage and Part D programs. This favorable adjustment is expected to bolster the company's revenue streams and profitability, as these programs represent a substantial portion of Alignment Healthcare's business. Investors are reacting positively to the improved financial outlook, anticipating enhanced earnings and a stronger market position for the healthcare provider.

  • 3/19/2026POSITIVE
    Align Technology Shares Jump Following Report Of Large Elliott Position

    Align Technology shares surged following news that activist investor Elliott Investment Management has taken a significant stake in the company. Elliott's involvement typically signals a push for strategic changes, often aimed at unlocking shareholder value. The move comes as Align Technology, the maker of Invisalign, faces challenges in its post-pandemic growth trajectory. Investors are likely interpreting this as a potential catalyst for operational improvements and a re-evaluation of the company's strategic direction, which could lead to enhanced financial performance.

  • 3/19/2026NEUTRAL
    Elliott Builds Stake in Invisalign-Maker Align Technology

    Hedge fund Elliott Investment Management has acquired a substantial stake in Align Technology Inc., the company renowned for its Invisalign clear aligners. This move by a prominent activist investor suggests potential for strategic changes or operational improvements within Align Technology. While the specific intentions of Elliott are not yet disclosed, such stake-building often precedes engagement with management to unlock shareholder value. Investors will be watching closely for any strategic shifts or performance enhancements that Elliott may advocate for, which could impact the company's future trajectory and stock performance.

via Markets Gazette